Internet Pioneer In...
Health Care: Drugs
Compugen Ltd. (CGEN: NASDAQ)
$3.41 -0.12 | -3.40%
06/01/12 - 04:00 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 5.85M | 7.30M | 15.14M | 5.42M |
| Receivables | 546.00K | 5.57M | 8.51M | 593.00K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 500.00K | 0.00 |
| Total Current Assets | 23.01M | 28.08M | 24.31M | 12.11M |
| Property, Plant & Equipment, Gross | 8.65M | 8.55M | 8.61M | 9.14M |
| Accumulated Depreciation & Depletion | 8.15M | 7.97M | 7.88M | 8.09M |
| Property, Plant & Equipment, Net | 497.00K | 580.00K | 735.00K | 1.06M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 5.58M | 7.80M | 5.14M | 1.08M |
| Total Non-Current Assets | 6.07M | 8.38M | 5.88M | 2.14M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 29.08M | 36.46M | 30.18M | 14.24M |
| Accounts Payable | 1.71M | 2.44M | 1.36M | 2.88M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 12.00K |
| Total Current Liabilities | 1.71M | 2.44M | 1.47M | 2.99M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 7.79M | 5.73M | 1.32M | 1.25M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 7.79M | 5.73M | 1.32M | 1.25M |
| Total Liabilities | 9.50M | 8.17M | 2.79M | 4.24M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 19.58M | 28.28M | 27.40M | 10.00M |
| Common Par | 94.00K | 92.00K | 88.00K | 77.00K |
| Additional Paid In Capital | 195.71M | 190.28M | 184.52M | 163.18M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -180.49M | -168.49M | -161.28M | -157.45M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 4.26M | 6.40M | 4.07M | 4.20M |
| Total Capitalization | 19.58M | 28.28M | 27.40M | 10.00M |
| Total Equity | 19.58M | 28.28M | 27.40M | 10.00M |
| Total Liabilities & Stock Equity | 29.08M | 36.46M | 30.18M | 14.24M |
| Total Common Shares Outstanding | 34.71M | 33.92M | 32.87M | 28.51M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 34.28M | 33.28M | 28.61M | 28.43M |
| Diluted Weighted Shares Outstanding | 34.28M | 33.28M | 28.61M | 28.43M |
| Number of Employees | 39 | 39 | 37 | 57 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with CGEN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Bargain Biotech Stocks
- Userdesignbydiana Portfolio 1
- Userraveha1 Portfolio 1
- ContributorBiotech Short Squeezes
- UserSUPRATRADE-QUANTUM STARDUST 8
- UserHumelor Portfolio 1
Latest CGEN Headlines from TheStreet
- 7 Stocks Under $10 Soaring Higher 05.24.12 | 12:05 pm
- 5 Bargain Biotech Stocks 01.13.11 | 05:01 pm
- Maguire Properties, Compugen: Midday Volume Plays 05.11.10 | 11:05 am
- eOn Communications, Compugen: Early Volume Plays 03.16.10 | 09:03 am
- Pluristem Therapeutics, Compugen: Early Volume Plays 03.02.10 | 09:03 am
- Array BioPharma, Sterling Financial: Early Volume Plays 02.02.10 | 09:02 am
- Biotech's Movers & Shakers 2009: BioBuzz 01.04.10 | 09:01 am
- Compugen, Flotek: Early Volume Plays 01.04.10 | 07:01 am
- China BAK, Compugen: Early Volume Plays 12.30.09 | 08:12 am
- Compugen, Sinovac: Early Volume Plays 12.28.09 | 08:12 am
Press Releases for CGEN
- Dr. Mary Haak-Frendscho, Chairperson Of Compugen’s US Subsidiary, To Give Keynote Address At China Pharmaceutical R&D Summit - Business Wire 04.23.12 | 07:04 am
- Compugen First Quarter 2012 Conference Call Scheduled For Tuesday, May 1, 2012 At 10:00 AM EST - Business Wire 04.23.12 | 07:04 am
- Compugen Presents Prediction Based Discovery Strategy At “Targets And Strategies For Drug Discovery” Conference - Business Wire 02.27.12 | 07:02 am
- Compugen Cancer Target Results Demonstrate Significant Potential For Cancer Immunotherapy - Business Wire 02.02.12 | 06:02 am
- Compugen To Broaden And Accelerate Monoclonal Antibody Program For Oncology And Immunology - Business Wire 12.20.11 | 10:12 am
- BioLineRx To Develop And Commercialize Novel Peptide Drug Candidates Discovered By Compugen - Business Wire 12.13.11 | 06:12 am
- Compugen Presents Predictive Drug Target Discovery Platform At European Antibody Conference - Business Wire 11.30.11 | 07:11 am
- Www.discoverx.com - Business Wire 11.29.11 | 07:11 am
- Compugen Reports Third Quarter 2011 Financial Results - Business Wire 11.08.11 | 07:11 am
- Compugen's CGEN-15001 Pre-Clinical Data Presented At International Conference On Immune Tolerance - Business Wire 10.25.11 | 07:10 am
Partner Headlines for CGEN
- Life Sciences Companies Raise Record Amounts of Capital - Seeking Alpha 12.31.10 | 04:12 pm
- Compugen: On the Road to Breakthroughs - Seeking Alpha 05.12.10 | 03:05 am
